Drug major Lupin on Friday said it has received an establishment inspection report (EIR) from the US health regulator after inspection of its Nagpur facility in Maharashtra.
The United States Food and Drug Administration (USFDA) conducted the inspection between August 5-8, 2019, Lupin said in a filing to the BSE.
The inspection for the oral solid facility closed without any Form 483 observation, it added. Form 483 notifies the company's management of objectionable conditions.
The Nagpur facility is the company's largest and most advanced oral solid dosage facility and has maintained a solid track record of compliance, Lupin said.
"Excelling at quality and compliance is one of our top priorities and we remain committed to meeting and exceeding standards set by regulatory agencies globally," Lupin MD Nilesh Gupta said.
Shares of Lupin were trading at Rs 740.30 per scrip on BSE, up 1.91 per cent from the previous close.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app